Horizon Pharma Inc., a Northbrook, Ill.-based drug developer focused on arthritis, pain and inflammatory diseases, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol HZNP, with Jefferies & Co. and Piper Jaffray serving as co-lead underwriters.
The company has raised around $54 million in VC funding since its 2004 founding as Nitec Pharma. Shareholders include Atlas Venture (17.4% pre-IPO stake), Essex Woodlands Health Ventures (14%), Scale Venture Partners (13.4%), NGN Biomed (9.9%), Sutter Hill Ventures (5.9%), FirstMark Capital (7.9%), Global Life Sciences Ventures (7.8%) and TVM (5.7%). www.nitecpharma.com
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.